A180400 Stock Overview
Engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Dx & Vx Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,100.00 |
| 52 Week High | ₩7,280.00 |
| 52 Week Low | ₩1,639.00 |
| Beta | -0.026 |
| 11 Month Change | -12.31% |
| 3 Month Change | -26.01% |
| 1 Year Change | -55.40% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.95% |
Recent News & Updates
Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% Lower
Jul 15
Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%
May 31Recent updates
Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% Lower
Jul 15Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%
May 31Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% Hiding
Mar 18Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of Debt
Mar 08Shareholder Returns
| A180400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -17.6% | 1.5% | 1.9% |
| 1Y | -55.4% | 38.5% | 5.0% |
Return vs Industry: A180400 underperformed the KR Biotechs industry which returned 38.5% over the past year.
Return vs Market: A180400 underperformed the KR Market which returned 5% over the past year.
Price Volatility
| A180400 volatility | |
|---|---|
| A180400 Average Weekly Movement | 20.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A180400's share price has been volatile over the past 3 months.
Volatility Over Time: A180400's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 110 | Yong Gu Lee | www.dxvx.com |
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs.
Dx & Vx Co., Ltd. Fundamentals Summary
| A180400 fundamental statistics | |
|---|---|
| Market cap | ₩93.68b |
| Earnings (TTM) | -₩32.25b |
| Revenue (TTM) | ₩48.19b |
1.9x
P/S Ratio-2.9x
P/E RatioIs A180400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A180400 income statement (TTM) | |
|---|---|
| Revenue | ₩48.19b |
| Cost of Revenue | ₩37.03b |
| Gross Profit | ₩11.16b |
| Other Expenses | ₩43.41b |
| Earnings | -₩32.25b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07k |
| Gross Margin | 23.16% |
| Net Profit Margin | -66.92% |
| Debt/Equity Ratio | 248.8% |
How did A180400 perform over the long term?
See historical performance and comparison